Last reviewed · How we verify
NCT05262101
Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
Phase 2 trial testing TQB2858 injection in Advanced High-grade Sarcoma in 7 participants. Terminated before completion.
28 June 2023
Quick facts
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 9 May 2022 |
| Primary completion | 28 June 2023 |
| Estimated completion | 30 November 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- TQB2858 injection — full drug profile →
Conditions studied
- Advanced High-grade Sarcoma — all drugs for Advanced High-grade Sarcoma →
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Advanced High-grade Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, open-label, multicenter Phase Ib clinical trial evaluating TQB2858 injection in the treatment of advanced high-grade sarcoma. To evaluate the preliminary efficacy and safety of TQB2858 injection in patients with advanced high-grade sarcoma, and to explore the relevant biomarkers of TQB2858 injection.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513 -
Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review.
Masuda H. · · 2025 · cited 11× · PMID 40707476 · DOI 10.1038/s41420-025-02566-x
Verify or expand the search:
- PubMed search for NCT05262101
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TQB2858 injection
Trials testing the same drug.
- NCT05193604 — A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcino · Phase 1 · terminated
- NCT05154630 — Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors · Phase 1, PHASE2 · terminated
- NCT04805060 — A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors · Phase 1 · unknown
Other Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07052097 — Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis · Phase 2 · completed
- NCT06929195 — Clinical Trial to Evaluate the Tolerance of TQB2210 Injection · Phase 1 · completed
- NCT06542614 — Treatment of Moderate to Severe Plaque Psoriasis · Phase 2 · completed
- NCT06451640 — A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps · Phase 2 · completed
- NCT06438783 — TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05262101 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Last refreshed: 22 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05262101.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing